8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 26, 2004

LA JOLLA PHARMACEUTICAL COMPANY

(Exact Name of Registrant as Specified in Charter)

Delaware	0-24274	33-0361285
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6455 Nancy Ridge Drive
San Diego, California 92121
(Address of Principal Executive Offices, Including Zip Code)

Registrant’s telephone number, including area code: (858) 452-6600

TABLE OF CONTENTS

	Item 5. Other Events and Required FD Disclosure.
	Item 7. Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

Item 5. Other Events and Required FD Disclosure.

     On February 26, 2004, La Jolla Pharmaceutical Company issued a press release announcing that it had completed its previously announced public offering of 8,695,653 shares of common stock. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 7. Exhibits.

(c) Exhibits:

     The following exhibits are filed with this Report on Form 8-K:

Exhibit No.	Description
99.1	Press Release, dated February 26, 2004

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 26, 2004
	LA JOLLA PHARMACEUTICAL COMPANY
	By:	/s/ Steven B. Engle
		Steven B. Engle
		Chairman and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release, dated February 26, 2004

EX-99.1

                                                                    Exhibit 99.1

                         LA JOLLA PHARMACEUTICAL COMPANY
                            COMPLETES STOCK OFFERING

      SAN DIEGO, CA, February 26, 2004 - La Jolla Pharmaceutical Company
announced today that it has completed its previously announced public offering
of 8,695,653 shares of common stock. The net proceeds to the Company from the
sale of the shares, after expenses, will be approximately $25.6 million. The
Company has also granted the underwriter an option to purchase up to an
additional 1,304,347 shares of common stock at the initial offering price to
cover over-allotments, if any.

      This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities of La Jolla Pharmaceutical
Company, and there shall be no sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction. A copy of the prospectus and accompanying prospectus
supplement relating to the offering can be obtained from Pacific Growth
Equities, LLC at 1 Bush Street, San Francisco, CA 94104.

      La Jolla Pharmaceutical Company is a biotechnology company developing
therapeutics for antibody-mediated autoimmune diseases afflicting several
million people in the United States and Europe.

      This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such statements involve
known and unknown risks, uncertainties and other factors that may cause actual
results to differ materially from current expectations.